Wesper Journal

GLP-1 Receptor Agonists and Obstructive Sleep Apnea (OSA): A New Era in Sleep Health ManagementThe approval of GLP-1 receptor agonists, such as Zepbound (tirzepatide), represents a groundbreaking development in the treatment of Obstructive Sleep Apnea (OSA). These medications not only...

This article explores the relationship between BMI, age, and gender in obstructive sleep apnea (OSA) severity and hypoxic burden. Analyzing two patient cohorts, the study finds that higher BMI is linked to increased apnea-hypopnea index (AHI) and hypoxic burden, though its effect plateaus in severe obesity. Age and male gender emerge as stronger predictors of OSA severity in obese individuals. The findings highlight the potential of GLP-1-induced weight loss to reduce OSA severity but emphasize the need for a multimodal approach, integrating weight management with traditional OSA treatments like CPAP for optimal patient outcomes.

Discover how Zepbound® (tirzepatide), the first FDA-approved medication for obstructive sleep apnea (OSA) in adults with obesity, is revolutionizing treatment. Combining effective weight management with symptom relief, Zepbound offers a groundbreaking solution that enhances sleep quality, simplifies care pathways, and improves overall health outcomes. Learn more about this transformative advancement in OSA therapy.